|
NEW
CME ACTIVITY 
After
completing this activity, clinicians will have gained a working knowledge of the
most recent US Department of Health and Human Services (DHHS) guidelines for the
use of antiretroviral therapy (ART) and be familiar with the results from the
most recent study data on specific risks and benefits of specific ART with respect
to the overall health of the patient. With this knowledge, clinicians will understand
the benefits and risks of early ART initiation and be better able to choose optimal
antiviral agents for their patients at the beginning of HIV treatment as well
as manage long-term therapy, taking into account resistance, aging, and the whole
health of the patient. 
This
program is designed for health care practitioners (physicians, nurses, physician
assistants, nurse practitioners, and pharmacists) involved in the management of
patients with HIV. 
At
the completion of this program, participants will be better able to:
• | DISCUSS
the changes to the DHHS guidelines, evaluate the benefits and risks of various
recommended ART regimens, and define the most important factors for choosing appropriate
ART in a treatment-naïve HIV patient |
| • | ASSESS
the concept of stable therapy and describe the circumstances in which it is appropriate
to switch a virologically-suppressed HIV patient to a different ART regimen |
| • | DEVELOP
and implement strategies to identify and manage antiretroviral resistance in order
to optimize long-term vital suppression |
| • | ASSESS
the role of recently FDA-approved ART agents in the management of HIV infection
and develop strategies to integrate the new agents into current treatment paradigms |
| • | RECOGNIZE
the role of comorbidities (eg, hepatitis B or C (HBV or HCV) coinfection, cardiovascular
disease, renal disease, diabetes, dyslipidemia) when choosing appropriate ART
regimens and articulate how specific ART choices interact with those comorbidities.
|
|
| | |
  | NURSING
Creative
Educational Concepts, Inc. (CEC) is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center's Commission on Accreditation.
CEC
provides this activity for 2.0 contact hours. Learners
are advised that accredited status does not imply endorsement by the provider
or ANCC of any commercial products discussed in conjunction with an activity.
|  | PHARMACY
The University of Kentucky College of Pharmacy is approved by the
Accreditation Council for Pharmacy Education as a provider of continuing pharmacy
education. This
program has been assigned ACPE # 022-999-08-128-H02-P and will award 2.0 contact
hours (0.20 CEUs) of continuing pharmacy education credit in states that recognize
ACPE providers. Statements
of credit will indicate hours and CEUs based on participation and will be issued
online at the conclusion of the activity. Successful completion includes signing
in at registration, attending the entire session for which credit is claimed,
completing the activity evaluation and requesting credit online at conclusion
of the activity. The College complies with the Criteria for Quality for continuing
education programming.
| | | MEDICINE
This
activity has been planned and implemented in accordance with the Essential Areas
and Policies of the Accreditation Council for Continuing Medical Education through
the joint sponsorship of the University of Kentucky College of Medicine and HealthmattersCME.
The University of Kentucky College of Medicine is accredited by the ACCME to provide
continuing medical education for physicians. The
University of Kentucky College of Medicine designates this educational activity
for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should
only claim credit commensurate with the extent of their participation in the activity. The
University of Kentucky College of Medicine presents this activity for educational
purposes only. Participants are expected to utilize their own expertise and judgment
while engaged in the practice of medicine. The content of the presentations is
provided solely by presenters who have been selected for presentations because
of recognized expertise in their field. |
All
faculty members participating in continuing medical education programs sponsored
by the University of Kentucky Colleges of Pharmacy and Medicine are expected to
disclose any real or perceived conflict of interest related to the content of
their presentations. Copies of faculty disclosures will be given prior to the
activity. University
of Kentucky is an Equal Opportunity University.
The
University of Kentucky Colleges of Pharmacy and Medicine adheres to ACCME and
ANCC Essential Areas and Policies, including the Standards for Commercial Support
regarding industry support of continuing medication education. In order to resolve
any identified conflicts of interest, disclosure information is provided during
the planning process to ensure resolution of any identified conflicts. Disclosure
of faculty and commercial relationships, as well as the discussion of unlabeled/investigational
use of any drug, device, or procedure by the faculty, are made known below. John
G. Bartlett, MD •
| HIV
Advisory Board: Abbott, GlaxoSmithKline, Bristol-Myers Squibb, Tibotec, Pfizer | •
| Policy
Advisory Board: Johnson & Johnson | •
| Contract
research support: Gilead Sciences, Inc. |
Calvin
J. Cohen, MD
•
| Speaker's
Bureau: GlaxoSmithKline, Bristol-Myers Squibb, Gilead Sciences, Tibotec, Merck,
Pfizer Inc | •
| Contract
research support: GlaxoSmithKline, Bristol-Myers Squibb, Gilead Sciences, Tibotec,
Merck, Pfizer Inc | •
| Consultant:
GlaxoSmithKline, Bristol-Myers Squibb, Gilead Sciences, Tibotec, Merck, Pfizer
Inc |
Sally
Hodder, MD •
| Speaker’s
Bureau: Bristol-Myers Squibb | | • | Contract
research support: Bristol-Myers Squibb, Gilead Sciences, Pfizer Inc, Tibotec | | • | Consultant:
Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Tibotec | | • | Spouse’s
financial interest: Retired Merck employee |
Martin
Markowitz, MD •
| Advisory
Board: Merck, Gilead Sciences, Sequoia, GlaxoSmithKline | •
| DSMB
Committee: Quintiles | •
| Speaker
Consultant: Merck |
Paul
E. Sax, MD •
| Consultant:
Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Tibotec | | •
| Teaching
Honoraria: Abbott, Bristol-Myers Squibb, Gilead Sciences, Merck, Tibotec
| | •
| Grant
support: Merck |
Launch:
December 3, 2008 | Expiration:
December 3, 2009 |
|
| | | |
|
|
